Sermorelin vs CJC-1295: GHRH Analog Comparison

Both sermorelin and CJC-1295 are synthetic analogs of growth hormone-releasing hormone (GHRH), and both are built on the same active fragment of that molecule — the first 29 amino acids, often written GRF(1-29). Because they share a receptor and a general purpose (stimulating the pituitary to release its own growth hormone), they are frequently searched side by side. Yet they sit at opposite ends of the class in one decisive respect: how long they stay active in circulation.

This comparison is written for researchers and writers trying to understand where the two peptides diverge in mechanism, pharmacokinetics, regulatory history, and evidence. It is not a usage guide.

Research-only notice. Sermorelin and CJC-1295 are discussed here strictly as research compounds. Sermorelin’s approved products have been discontinued, and CJC-1295 has never been approved for human use. Nothing below is medical advice, a dosing protocol, or a recommendation for human administration.

Mechanism: the same receptor, a very different clock

At the molecular level these two peptides do the same thing. Each binds the GHRH receptor on somatotroph cells in the anterior pituitary, activates adenylyl cyclase, raises intracellular cyclic AMP, and prompts the cell to secrete stored growth hormone. Neither introduces growth hormone directly; both act one step upstream, so the pituitary’s own feedback signals — somatostatin and circulating IGF-I — can still modulate the response.

Sermorelin is the plain, unmodified GRF(1-29) sequence. It is the shortest peptide fragment that retains the full biological activity of native GHRH, but it carries GHRH’s fragility: dipeptidyl peptidase-IV (DPP-IV) cleaves it near the N-terminus within minutes, giving a plasma half-life of roughly 11-12 minutes. The result is a brief, sharp GH pulse that resembles the body’s own secretory bursts.

CJC-1295 was engineered to defeat that rapid clearance. Its backbone is a tetra-substituted GRF(1-29) (substitutions at positions 2, 8, 15, and 27 that resist DPP-IV). The name “CJC-1295” most precisely refers to the version carrying a Drug Affinity Complex (DAC): a maleimidoproprionyl linker that reacts with a thiol on cysteine-34 of serum albumin, tethering the peptide to a carrier protein that survives in blood for weeks. That single design choice stretches the half-life from minutes to an estimated 6-8 days and produces a sustained rise in GH and IGF-I rather than a discrete pulse. A separate, shorter-acting form — “CJC-1295 without DAC,” identical to Modified GRF(1-29) — keeps the stabilized backbone but omits the albumin anchor, giving a half-life closer to 30 minutes. The two forms behave nothing alike in circulation.

Evidence and development status

Sermorelin has the longer and better-documented clinical track record. It was approved as Geref for diagnostic use in the early 1990s and, later, for idiopathic growth hormone deficiency in children. A 1999 review by Prakash and Goa summarized its use as a rapid, relatively specific provocative test for GH deficiency and documented sustained increases in height velocity in prepubertal children over twelve months. Its manufacturer voluntarily discontinued the product around 2008-2009 as recombinant human growth hormone took over the market; regulators later confirmed the withdrawal was for commercial reasons, not safety or efficacy. It remains available through compounding pharmacies.

CJC-1295’s human evidence base is thinner and older. The most-cited study, Teichman and colleagues (2006), gave single subcutaneous doses to healthy adults and reported dose-dependent GH increases of two- to ten-fold lasting six or more days, with IGF-I rising 1.5- to 3-fold for up to nine to eleven days — direct confirmation of the long-acting design. A companion paper by Ionescu and Frohman (2006) showed that even under continuous stimulation, GH was still released in pulses rather than as a flat line. Beyond these early studies, development stalled: a Phase 2 trial in HIV-associated lipodystrophy was halted in 2006 after a participant died of a myocardial infarction (which investigators judged most likely unrelated to the drug), and the compound never advanced to Phase 3 or approval.

Research context

The two peptides appear in different investigative settings. Sermorelin’s short action and pulsatile profile made it a natural diagnostic probe of pituitary reserve and a tool for studying the physiological GH rhythm and its age-related decline. CJC-1295 is studied where a prolonged, elevated GH/IGF-I signal is the object of interest — body-composition and metabolic models — because a single administration can maintain elevated hormone levels for most of a week. That convenience carries a trade-off: sustained stimulation departs from the body’s natural pulsatile pattern, one reason the Ionescu-Frohman finding of preserved pulsatility drew attention.

Key differences

• Duration: sermorelin’s half-life is measured in minutes; CJC-1295 with DAC lasts days — the single largest distinction between them.
• Secretion pattern: sermorelin produces a brief, physiological-looking GH pulse; CJC-1295 (DAC) produces a sustained elevation of GH and IGF-I.
• Structure: sermorelin is native GRF(1-29); CJC-1295 is a stabilized, tetra-substituted GRF(1-29), and its signature form adds an albumin-binding complex.
• Regulatory history: sermorelin was once FDA-approved and is now compounded; CJC-1295 has never been approved and its clinical program was discontinued.
• Evidence depth: sermorelin has diagnostic and pediatric clinical data; CJC-1295’s human data are limited to a small number of early pharmacokinetic studies.
• Naming trap: “CJC-1295” alone can mean either the long-acting DAC form or the short-acting non-DAC form (Modified GRF(1-29)); the two are not interchangeable.

Which for what research?

Framed purely as research tools, the choice tracks the question being asked. Studies concerned with the natural pulsatile GH rhythm, with pituitary responsiveness, or with a compound that has an established diagnostic record tend to reference sermorelin, whose brief action mirrors endogenous secretion. Investigations that require a durable, sustained elevation of GH and IGF-I from infrequent administration — and can accept a much thinner, older evidence base and investigational-only status — are the context in which CJC-1295 (DAC form) is examined. The DAC-versus-non-DAC distinction should be resolved before any comparison is drawn, since the non-DAC variant behaves far more like sermorelin than like the long-acting compound that shares its name.

Put these side by side in the Compare Peptides tool.

Sources

• Teichman SL, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. PMID 16352683
• Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792-4797. PMID 17018654
• Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. 1999;12(2):139-157. PMID 18031173
• ClinicalTrials.gov. A Study to Evaluate CJC-1295 in HIV Patients With Visceral Obesity (NCT00267527). NCT00267527